APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nucleic Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nucleic Vaccine Market Outlook and Growth Opportunities 2026

23 December 2025198 pages

Choose your research edition.

Industry ResearchNucleic Vaccine Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Nucleic Vaccine Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Nucleic Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nucleic Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Nucleic Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nucleic Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nucleic Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nucleic Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nucleic Vaccine market include CNBG, Zhifei Shengwu, Walvax Biotechnology, Sanofi, Liaoning Chengda, CanSinoBIO, BioKangtai, Hualan Bio and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nucleic Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nucleic Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nucleic Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nucleic Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Nucleic Vaccine Segment by Company

CNBG

Zhifei Shengwu

Walvax Biotechnology

Sanofi

Liaoning Chengda

CanSinoBIO

BioKangtai

Hualan Bio

GSK

Fosun Pharma

Moderna

Inovio

CureVac

Nucleic Vaccine Segment by Type

Preventive Nucleic Vaccine

Therapeutic Nucleic Vaccine

Nucleic Vaccine Segment by Application

Hospital

Clinic

Others

Nucleic Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nucleic Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Nucleic Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nucleic Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Nucleic Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nucleic Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nucleic Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nucleic Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nucleic Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nucleic Vaccine industry.

Chapter 3: Detailed analysis of Nucleic Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Nucleic Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Nucleic Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nucleic Vaccine Industry Trends Table 2. Nucleic Vaccine Industry Drivers Table 3. Nucleic Vaccine Industry Opportunities and Challenges Table 4. Nucleic Vaccine Industry Restraints Table 5. Global Nucleic Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nucleic Vaccine Revenue Share by Company (2021-2026) Table 7. Global Nucleic Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Nucleic Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Nucleic Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Nucleic Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Nucleic Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Nucleic Vaccine Company, Product Type & Application Table 13. Global Nucleic Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Nucleic Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Preventive Nucleic Vaccine Table 18. Significant Companies of Therapeutic Nucleic Vaccine Table 19. Global Nucleic Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Nucleic Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Nucleic Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Nucleic Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Nucleic Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Nucleic Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Nucleic Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Nucleic Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Nucleic Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Nucleic Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global Nucleic Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Nucleic Vaccine Sales Volume by Application (2021-2026) & (k units) Table 34. Global Nucleic Vaccine Sales Volume by Application (2027-2032) & (k units) Table 35. Global Nucleic Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Nucleic Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Nucleic Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Nucleic Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Nucleic Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Nucleic Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Nucleic Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Nucleic Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Nucleic Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Nucleic Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Nucleic Vaccine Sales by Region (2027-2032) & (k units) Table 46. Global Nucleic Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Nucleic Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Nucleic Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Nucleic Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Nucleic Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Nucleic Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Nucleic Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Nucleic Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Nucleic Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Nucleic Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Nucleic Vaccine Sales by Country (2021-2026) & (k units) Table 57. Global Nucleic Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Nucleic Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Nucleic Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Nucleic Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Nucleic Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Nucleic Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Nucleic Vaccine Sales Value Market Share by Country (2027-2032) Table 64. CNBG Company Information Table 65. CNBG Business Overview Table 66. CNBG Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. CNBG Nucleic Vaccine Product Portfolio Table 68. CNBG Recent Development Table 69. Zhifei Shengwu Company Information Table 70. Zhifei Shengwu Business Overview Table 71. Zhifei Shengwu Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Zhifei Shengwu Nucleic Vaccine Product Portfolio Table 73. Zhifei Shengwu Recent Development Table 74. Walvax Biotechnology Company Information Table 75. Walvax Biotechnology Business Overview Table 76. Walvax Biotechnology Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Walvax Biotechnology Nucleic Vaccine Product Portfolio Table 78. Walvax Biotechnology Recent Development Table 79. Sanofi Company Information Table 80. Sanofi Business Overview Table 81. Sanofi Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Sanofi Nucleic Vaccine Product Portfolio Table 83. Sanofi Recent Development Table 84. Liaoning Chengda Company Information Table 85. Liaoning Chengda Business Overview Table 86. Liaoning Chengda Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Liaoning Chengda Nucleic Vaccine Product Portfolio Table 88. Liaoning Chengda Recent Development Table 89. CanSinoBIO Company Information Table 90. CanSinoBIO Business Overview Table 91. CanSinoBIO Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. CanSinoBIO Nucleic Vaccine Product Portfolio Table 93. CanSinoBIO Recent Development Table 94. BioKangtai Company Information Table 95. BioKangtai Business Overview Table 96. BioKangtai Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. BioKangtai Nucleic Vaccine Product Portfolio Table 98. BioKangtai Recent Development Table 99. Hualan Bio Company Information Table 100. Hualan Bio Business Overview Table 101. Hualan Bio Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Hualan Bio Nucleic Vaccine Product Portfolio Table 103. Hualan Bio Recent Development Table 104. GSK Company Information Table 105. GSK Business Overview Table 106. GSK Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. GSK Nucleic Vaccine Product Portfolio Table 108. GSK Recent Development Table 109. Fosun Pharma Company Information Table 110. Fosun Pharma Business Overview Table 111. Fosun Pharma Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Fosun Pharma Nucleic Vaccine Product Portfolio Table 113. Fosun Pharma Recent Development Table 114. Moderna Company Information Table 115. Moderna Business Overview Table 116. Moderna Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Moderna Nucleic Vaccine Product Portfolio Table 118. Moderna Recent Development Table 119. Inovio Company Information Table 120. Inovio Business Overview Table 121. Inovio Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Inovio Nucleic Vaccine Product Portfolio Table 123. Inovio Recent Development Table 124. CureVac Company Information Table 125. CureVac Business Overview Table 126. CureVac Nucleic Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. CureVac Nucleic Vaccine Product Portfolio Table 128. CureVac Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Nucleic Vaccine Distributors List Table 132. Nucleic Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Nucleic Vaccine Product Image Figure 2. Global Nucleic Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Nucleic Vaccine Sales (2021-2032) & (k units) Figure 5. Global Nucleic Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Nucleic Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Preventive Nucleic Vaccine Image Figure 10. Therapeutic Nucleic Vaccine Image Figure 11. Global Nucleic Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Nucleic Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Nucleic Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Nucleic Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Nucleic Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Nucleic Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global Nucleic Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Nucleic Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Nucleic Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Nucleic Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Nucleic Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Nucleic Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Nucleic Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Nucleic Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Nucleic Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Nucleic Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Nucleic Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Nucleic Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Nucleic Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Nucleic Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Nucleic Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Nucleic Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Nucleic Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Nucleic Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Nucleic Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Nucleic Vaccine
  • Therapeutic Nucleic Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • CNBG
  • Zhifei Shengwu
  • Walvax Biotechnology
  • Sanofi
  • Liaoning Chengda
  • CanSinoBIO
  • BioKangtai
  • Hualan Bio
  • GSK
  • Fosun Pharma
  • Moderna
  • Inovio
  • CureVac

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Nucleic Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Nucleic Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Nucleic Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Nucleic Vaccine Market Dynamics
  1. 2.1 Nucleic Vaccine Industry Trends
  2. 2.2 Nucleic Vaccine Industry Drivers
  3. 2.3 Nucleic Vaccine Industry Opportunities and Challenges
  4. 2.4 Nucleic Vaccine Industry Restraints
3 Nucleic Vaccine Market by Company
  1. 3.1 Global Nucleic Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Nucleic Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Nucleic Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Nucleic Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Nucleic Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Nucleic Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Nucleic Vaccine Company Product Type and Application
  8. 3.8 Global Nucleic Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Nucleic Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Nucleic Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Nucleic Vaccine Market by Type
  1. 4.1 Nucleic Vaccine Type Introduction
  2. 4.1.1 Preventive Nucleic Vaccine
  3. 4.1.2 Therapeutic Nucleic Vaccine
  4. 4.2 Global Nucleic Vaccine Sales Volume by Type
  5. 4.2.1 Global Nucleic Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Nucleic Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Nucleic Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Nucleic Vaccine Sales Value by Type
  9. 4.3.1 Global Nucleic Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Nucleic Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Nucleic Vaccine Sales Value Share by Type (2021-2032)
5 Nucleic Vaccine Market by Application
  1. 5.1 Nucleic Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Nucleic Vaccine Sales Volume by Application
  6. 5.2.1 Global Nucleic Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nucleic Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Nucleic Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Nucleic Vaccine Sales Value by Application
  10. 5.3.1 Global Nucleic Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Nucleic Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Nucleic Vaccine Sales Value Share by Application (2021-2032)
6 Nucleic Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Nucleic Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nucleic Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Nucleic Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Nucleic Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Nucleic Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Nucleic Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Nucleic Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Nucleic Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Nucleic Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Nucleic Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Nucleic Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Nucleic Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Nucleic Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Nucleic Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Nucleic Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Nucleic Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Nucleic Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Nucleic Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Nucleic Vaccine Sales Value Share by Country, 2025 VS 2032
7 Nucleic Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Nucleic Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nucleic Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Nucleic Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Nucleic Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Nucleic Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Nucleic Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Nucleic Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Nucleic Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Nucleic Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Nucleic Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Nucleic Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CNBG
  2. 8.1.1 CNBG Company Information
  3. 8.1.2 CNBG Business Overview
  4. 8.1.3 CNBG Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CNBG Nucleic Vaccine Product Portfolio
  6. 8.1.5 CNBG Recent Developments
  7. 8.2 Zhifei Shengwu
  8. 8.2.1 Zhifei Shengwu Company Information
  9. 8.2.2 Zhifei Shengwu Business Overview
  10. 8.2.3 Zhifei Shengwu Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhifei Shengwu Nucleic Vaccine Product Portfolio
  12. 8.2.5 Zhifei Shengwu Recent Developments
  13. 8.3 Walvax Biotechnology
  14. 8.3.1 Walvax Biotechnology Company Information
  15. 8.3.2 Walvax Biotechnology Business Overview
  16. 8.3.3 Walvax Biotechnology Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Walvax Biotechnology Nucleic Vaccine Product Portfolio
  18. 8.3.5 Walvax Biotechnology Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Nucleic Vaccine Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Liaoning Chengda
  26. 8.5.1 Liaoning Chengda Company Information
  27. 8.5.2 Liaoning Chengda Business Overview
  28. 8.5.3 Liaoning Chengda Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Liaoning Chengda Nucleic Vaccine Product Portfolio
  30. 8.5.5 Liaoning Chengda Recent Developments
  31. 8.6 CanSinoBIO
  32. 8.6.1 CanSinoBIO Company Information
  33. 8.6.2 CanSinoBIO Business Overview
  34. 8.6.3 CanSinoBIO Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 CanSinoBIO Nucleic Vaccine Product Portfolio
  36. 8.6.5 CanSinoBIO Recent Developments
  37. 8.7 BioKangtai
  38. 8.7.1 BioKangtai Company Information
  39. 8.7.2 BioKangtai Business Overview
  40. 8.7.3 BioKangtai Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 BioKangtai Nucleic Vaccine Product Portfolio
  42. 8.7.5 BioKangtai Recent Developments
  43. 8.8 Hualan Bio
  44. 8.8.1 Hualan Bio Company Information
  45. 8.8.2 Hualan Bio Business Overview
  46. 8.8.3 Hualan Bio Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hualan Bio Nucleic Vaccine Product Portfolio
  48. 8.8.5 Hualan Bio Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GSK Nucleic Vaccine Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Fosun Pharma
  56. 8.10.1 Fosun Pharma Company Information
  57. 8.10.2 Fosun Pharma Business Overview
  58. 8.10.3 Fosun Pharma Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Fosun Pharma Nucleic Vaccine Product Portfolio
  60. 8.10.5 Fosun Pharma Recent Developments
  61. 8.11 Moderna
  62. 8.11.1 Moderna Company Information
  63. 8.11.2 Moderna Business Overview
  64. 8.11.3 Moderna Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Moderna Nucleic Vaccine Product Portfolio
  66. 8.11.5 Moderna Recent Developments
  67. 8.12 Inovio
  68. 8.12.1 Inovio Company Information
  69. 8.12.2 Inovio Business Overview
  70. 8.12.3 Inovio Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Inovio Nucleic Vaccine Product Portfolio
  72. 8.12.5 Inovio Recent Developments
  73. 8.13 CureVac
  74. 8.13.1 CureVac Company Information
  75. 8.13.2 CureVac Business Overview
  76. 8.13.3 CureVac Nucleic Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 CureVac Nucleic Vaccine Product Portfolio
  78. 8.13.5 CureVac Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nucleic Vaccine Value Chain Analysis
  2. 9.1.1 Nucleic Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nucleic Vaccine Sales Mode & Process
  6. 9.2 Nucleic Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nucleic Vaccine Distributors
  9. 9.2.3 Nucleic Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst